drugset / Trial / NCT05214794
An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy of nemolizumab in systemic sclerosis patients. To evaluate also the safety and pharmacokinetics.
Timeline
- Start
- 2022-04-20
- Primary completion
- 2024-06-04
- Completion
- 2024-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemolizumab | Monoclonal antibody | — | Subcutaneous |